Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Receivables (2016 - 2023)

Spyre Therapeutics' Change in Receivables history spans 7 years, with the latest figure at -$163000.0 for Q4 2023.

  • For Q4 2023, Change in Receivables rose 44.56% year-over-year to -$163000.0; the TTM value through Sep 2024 reached -$163000.0, up 67.79%, while the annual FY2023 figure was -$375000.0, 14.77% up from the prior year.
  • Change in Receivables reached -$163000.0 in Q4 2023 per SYRE's latest filing, up from -$1.5 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $21.5 million in Q1 2021 to a low of -$21.5 million in Q2 2021.
  • Average Change in Receivables over 3 years is $0.0, with a median of -$45000.0 recorded in 2023.
  • The largest YoY upside for Change in Receivables was 346.9% in 2023 against a maximum downside of 880.53% in 2023.
  • A 3-year view of Change in Receivables shows it stood at $815000.0 in 2021, then crashed by 136.07% to -$294000.0 in 2022, then soared by 44.56% to -$163000.0 in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Change in Receivables are -$163000.0 (Q4 2023), -$1.5 million (Q3 2023), and $1.3 million (Q2 2023).